IgE, His & Avi, Human
IgE, His & Avi, Human

Immobilized IgE, His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-IgE Antibody, hFc Tag with the EC50 of 5.1 ng/ml determined by ELISA.

IgE, His & Avi, Human

IgE, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

IgE, His & Avi, Human

Immunoglobulin E (IgE) is well known for its role in allergic disease, the manifestations of which are mediated through its two Fc receptors, FcεRI and CD23 (FcεRII). IgE and its interactions with these receptors are therefore potential targets for therapeutic intervention, and exciting progress has been made in this direction. Furthermore, recent structural studies of IgE-Fc, the two receptors, and of their complexes, have revealed a remarkable degree of plasticity at the IgE-CD23 interface and an even more remarkable degree of dynamic flexibility within the IgE molecule.
Z05403
¥87,675.00

Ask us a question
Product Introduction
Species Human
Protein Construction
IgE (Cys209-Lys428)
Accession # P01854-1		 His Avi
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized IgE, His & Avi, Human at 0.5μg/ml (100μl/well) on the plate can bind Anti­IgE Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 27.8 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 30-35 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 20mM PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • IgE, His & Avi, Human
    • IgE, His & Avi, Human

    Immobilized IgE, His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-IgE Antibody, hFc Tag with the EC50 of 5.1 ng/ml determined by ELISA.

  • IgE, His & Avi, Human
    • IgE, His & Avi, Human

    IgE, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Immunoglobulin E (IgE) is well known for its role in allergic disease, the manifestations of which are mediated through its two Fc receptors, FcεRI and CD23 (FcεRII). IgE and its interactions with these receptors are therefore potential targets for therapeutic intervention, and exciting progress has been made in this direction. Furthermore, recent structural studies of IgE-Fc, the two receptors, and of their complexes, have revealed a remarkable degree of plasticity at the IgE-CD23 interface and an even more remarkable degree of dynamic flexibility within the IgE molecule.
Synonyms Ig epsilon chain C region;IgE

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.